sEH-IN-21 

sEH-IN-21 is an orally active sEH inhibitor with IC₅₀50s of 0.1 nM for hsEH and msEH. sEH-IN-21 potently inhibits NF-κB signaling pathways. sEH-IN-21 shows a strong anti-inflammatory activity, decreases the release of IL-6 and TNF-α and maintained the integrity of the intestinal barrier. sEH-IN-21 can be used for the study of inflammatory bowel disease (IBD)^[1].

sEH-IN-21 (Compound A1) has moderate metabolic stability in rat liver microsomes, with a half-life of 13.51 min and a plasma protein binding rate of 96.2%. ^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

sEH-IN-21 (Compound A1) (25-100 mg/kg, p.o., for 10 days) shows anti-inflammatory activity and could alleviated the severity of DSS (HY-116282C) induced acute colitis in mouse by improving the intestinal mucosa barrier function^[1].
sEH-IN-21 (1 g/kg, i.g., for 7 days) is well tolerated and has an excellent margin of safety in mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

568.73

C₃₀H₄₀N₄O₅S

3084814-46-7

O=C1C(N[C@@H]2CC[C@@H](NC(N[C@]3(C4)C[C@H](C5)C[C@]4(C)C[C@@]5(C)C3)=O)CC2)=C(NS(C6=CC=C(C)C=C6)(=O)=O)C1=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Xu H, et al. Design and Synthesis of Novel sEH Inhibitors for the Treatment of Inflammatory Bowel Disease. J Med Chem. 2025 Jul 1.  [Content Brief]